Dr. Douglas Earl Laux, MD

Dr. Laux practices at University of Iowa Health Care Medical Center in Iowa City, Iowa, part of The University of Iowa.

Dr. Laux's NPI, 1295946218, was assigned on May 24, 2007. Dr. Laux graduated from University of Missouri, Columbia School of Medicine in 2005. Dr. Laux holds Iowa license MD-37888.

Dr. Laux's primary practice is University of Iowa Health Care Medical Center, at 200 Hawkins Drive, Iowa City, IA 52242 in Johnson County. The practice phone is (319) 356-1616.

Dr. Laux's primary practice is University of Iowa Health Care Medical Center in Iowa City, Iowa, part of The University of Iowa. Dr. Laux is also affiliated with University of Iowa Health Care Medical Center Downtown. The medical group on file is Scanlan Center for School Mental Health Clinic. Dmand AI also links Dr. Laux to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laux practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Laux's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Laux's licenses on file in 3 states: Iowa, Missouri and Ohio.

CMS data shows 727 Medicare services from Dr. Laux across 8 procedure codes in 2024, for 241 Medicare patients. Medicare paid $50,316 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 241 Medicare patients who saw Dr. Laux in 2024. The largest group is 65 to 74, with 117 patients. 71% of them have high blood pressure, and 58% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Laux's median patient age at 74, with 34% women.

In 2024, Dr. Laux wrote 1,314 Medicare Part D claims for 178 patients. 77% of them were for generic drugs. CMS names the drug for 1,060 of them, across 25 drugs with 11 or more claims each, at $2,147,987 in total drug cost. In 2023, CMS named 761 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Laux for performance year 2024, reported as part of a group. Dr. Laux accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Laux as offering telehealth.

Dmand AI links 11 papers to Dr. Laux, published from 2014 to 2025. 2019 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Squamous Cell Carcinoma of Head and Neck. Dr. Laux has published most often in J Immunother Cancer. Dr. Laux's most frequent co-authors are Muhammad Furqan, MD, David A. Katz, MD and Carryn M. Anderson, MD.

Dmand AI links Dr. Laux to 4 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck and Carcinoma, Squamous Cell. Open Payments lists research payments to Dr. Laux that name 3 trials.

CMS Open Payments shows 14 general payments to Dr. Laux from 2 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 96% of the total. Eisai Inc. paid the most, $4,168. It also lists 8 research payments totaling $3,913 in 2025, naming 3 clinical trials.

Dr. Laux graduated from University of Missouri, Columbia School of Medicine in 2005.